Comorbid disease burden among MS patients 1968-2012: A Swedish register-based cohort studyShow others and affiliations
2021 (English)In: Multiple Sclerosis Journal, ISSN 1352-4585, E-ISSN 1477-0970, Vol. 27, no 2, p. 268-280Article in journal (Refereed) Published
Abstract [en]
BACKGROUND: People with multiple sclerosis (pwMS) have increased comorbid disease (CMD) risk. Most previous studies have not considered overall CMD burden.
OBJECTIVE: To describe lifetime CMD burden among pwMS.
METHODS: PwMS identified using Swedish registers between 1968 and 2012 (n = 25,476) were matched by sex, age, and county of residence with general-population comparators (n = 251,170). Prevalence, prevalence ratios (PRs), survival functions, and hazard ratios by MS status, age, and time period compared seven CMD: autoimmune, cardiovascular, depression, diabetes, respiratory, renal, and seizures.
RESULTS: The magnitude of the PRs for each CMD and age group decreased across time, with higher PRs in earlier time periods. Before 1990, younger age groups had higher PRs, and after 1990, older age groups had higher PRs. Male pwMS had higher burden compared with females. Overall, renal, respiratory, and seizures had the highest PRs. Before 2001, 50% of pwMS received a first/additional CMD diagnosis 20 years prior to people without MS, which reduced to 4 years after 2001. PwMS had four times higher rates of first/additional diagnoses in earlier time periods, which reduced to less than two times higher in recent time periods compared to people without MS.
CONCLUSION: Swedish pwMS have increased CMD burden compared with the general population, but this has reduced over time.
Place, publisher, year, edition, pages
Sage Publications, 2021. Vol. 27, no 2, p. 268-280
Keywords [en]
Multiple sclerosis, Sweden, burden, chronic disease, cohort, comorbidity, prevalence, registries
National Category
Geriatrics
Identifiers
URN: urn:nbn:se:oru:diva-80606DOI: 10.1177/1352458520910497ISI: 000523823900001PubMedID: 32162580Scopus ID: 2-s2.0-85081959730OAI: oai:DiVA.org:oru-80606DiVA, id: diva2:1414540
Note
Funding Agencies:
Hoffmann-La Roche
Novartis Pharma AG
2020-03-132020-03-132023-12-08Bibliographically approved